DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

02575 XUANZHUBIO-B

Closed Add to Porfolio
Index Constituent : None
Major Shareholders [00460] Sihuan Pharmaceutical Holdings Group Limited (49.13%)
Metropolitan Industrial Investment Fund (Limited Partnership) (13.52%)
Tianjin Zhenxuan Pharmaceutical Technology Partnership (Limited Partnership) (6.96%)		 Sector Health Care & Biotechnology
Web Site http://www.xuanzhubio.com Tel (86 010) 5765-4567
Email xzgroup@xuanzhubio.comxzgroup@xuanzhubio.com Fax N/A
Related Equities N/A
Principal Activities The Group is principally engaged in the research and development of new molecular entity drugs, and its business scope include: research, development, transfer, technical services and sales of new pharmaceutical and chemical technologies and new pharmaceutical products in the People’s Republic of China (the “PRC”).

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top